XmAb5871

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

IgG4-RD

Conditions

IgG4-RD

Trial Timeline

Mar 1, 2016 → Dec 1, 2017

About XmAb5871

XmAb5871 is a phase 2 stage product being developed by Xencor for IgG4-RD. The current trial status is completed. This product is registered under clinical trial identifier NCT02725476. Target conditions include IgG4-RD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02867098Phase 1Completed
NCT02725476Phase 2Completed